A novel platinum complex of the histone deacetylase inhibitor belinostat: Rational design, development and in vitro cytotoxicity

被引:31
作者
Parker, James P. [1 ]
Nimir, Hassan [2 ]
Griffith, Darren M. [1 ]
Duff, Brian [3 ]
Chubb, Anthony J. [4 ]
Brennan, Marian P. [5 ]
Morgan, Maria P. [5 ]
Egan, Denise A. [3 ]
Marmion, Celine J. [1 ]
机构
[1] Royal Coll Surgeons Ireland, Dept Pharmaceut & Med Chem, Ctr Synth & Chem Biol, Dublin 2, Ireland
[2] Univ Qatar, Coll Arts & Sci, Dept Chem & Earth Sci, Doha, Qatar
[3] Dublin Inst Technol, Dept Sci, Ctr Pharmaceut Res & Dev, Dublin 24, Ireland
[4] Natl Univ Ireland Univ Coll Dublin, Complex & Adapt Syst Lab, Dublin 4, Ireland
[5] Royal Coll Surgeons Ireland, Dublin 2, Ireland
基金
爱尔兰科学基金会;
关键词
Platinum; Histone deacetylases; Histone deacetylase inhibitors; Belinostat; Anti-cancer; Cytotoxicity; CRYSTAL-STRUCTURE; ANTICANCER AGENT; OVARIAN-CANCER; SOLID TUMORS; ACID; CARBOPLATIN; HYDROLYSIS; RESISTANCE; CISPLATIN; LYMPHOMA;
D O I
10.1016/j.jinorgbio.2013.03.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The successful design and synthesis of a novel Pt complex of the histone deacteylase inhibitor belinostat are reported. Molecular modelling assisted in the identification of a suitable malonate derivative of belinostat (mal-p-Bel) for complexation to platinum. Reaction of [Pt(NH3)(2)(H2O)(2)](NO3)(2) with the disodium salt of mal-p-Bel gave cis-[Pt(NH3)(2)(mal-p-Bel(-2H))] (where -(2H) indicates that mal-p-Bel is doubly deprotonated) in excellent yield. An in vitro cytotoxicity study revealed that cis-[Pt(NH3)(2)(mal-p-Bel(-2H)] possesses (i) considerable cytotoxicity against reported ovarian cancer cell lines, (ii) enhanced cytotoxicity relative to the previously reported Pt histone deacetylase inhibitor conjugate, cis-[Pt-II(NH3)(2)(malSAHA(-2H))] and (iii) favourable cyto-selective properties as compared to cisplatin and belinostat. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:70 / 77
页数:8
相关论文
共 50 条
  • [31] Discovery of a novel histone deacetylase 8 inhibitor by virtual screening
    Lei Zhang
    Minyong Li
    Jinhong Feng
    Hao Fang
    Wenfang Xu
    Medicinal Chemistry Research, 2012, 21 : 152 - 156
  • [32] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Katherine E. Warren
    Cindy McCully
    Henrik Dvinge
    Jette Tjørnelund
    Maxwell Sehested
    Henri S. Lichenstein
    Frank M. Balis
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 433 - 437
  • [33] Vorinostat, a histone deacetylase inhibitor, as a potential novel treatment for psoriasis
    Samuelov, Liat
    Bochner, Ron
    Magal, Lee
    Malovitski, Kiril
    Sagiv, Nadav
    Nousbeck, Janna
    Keren, Aviad
    Fuchs-Telem, Dana
    Sarig, Ofer
    Gilhar, Amos
    Sprecher, Eli
    EXPERIMENTAL DERMATOLOGY, 2022, 31 (04) : 567 - 576
  • [34] Histone Deacetylase Inhibitor Belinostat Regulates Metabolic Reprogramming in Killing Kras-Mutant Human Lung Cancer Cells
    Peter, Rebecca
    Sarwar, Md. Shahid
    Wang, Yujue
    Su, Xiaoyang
    Kong, Ah-Ng
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [35] Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design
    Thangapandian, Sundarapandian
    John, Shalini
    Sakkiah, Sugunadevi
    Lee, Keun Woo
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (10) : 4409 - 4417
  • [36] Design, synthesis and in vitro evaluation of amidoximes as histone deacetylase inhibitors for cancer therapy
    Jiao, Peifu
    Jin, Peng
    Li, Chencan
    Cui, Lechao
    Dong, Lihua
    Pan, Bin
    Song, Wentong
    Ma, Liang
    Dong, Jinlong
    Song, Lei
    Jin, Xinjie
    Li, Faming
    Wan, Maosheng
    Lv, Zhitao
    Geng, Qiaohong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (19) : 4679 - 4683
  • [37] Discovery of a novel histone deacetylase 8 inhibitor by virtual screening
    Zhang, Lei
    Li, Minyong
    Feng, Jinhong
    Fang, Hao
    Xu, Wenfang
    MEDICINAL CHEMISTRY RESEARCH, 2012, 21 (02) : 152 - 156
  • [38] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Warren, Katherine E.
    McCully, Cindy
    Dvinge, Henrik
    Tjornelund, Jette
    Sehested, Maxwell
    Lichenstein, Henri S.
    Balis, Frank M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 433 - 437
  • [39] A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity
    Griffith, Darren
    Morgan, Maria P.
    Marmion, Celine J.
    CHEMICAL COMMUNICATIONS, 2009, (44) : 6735 - 6737
  • [40] Effect of the Histone Deacetylase (HDAC) Inhibitor Belinostat on the Expression of the Aryl Hydrocarbon Receptor and its Target Genes in Human Cell Cultures
    A. A. Akishina
    R. O. Cherezov
    Y. E. Vorontsova
    O. B. Simonova
    Russian Journal of Developmental Biology, 2022, 53 : 141 - 144